Abstract: Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.
Abstract: The present invention relates to novel carboxylic acid-substituted idebenone derivatives, skin treatment compositions containing these carboxylic acid-substituted idebenone derivatives, methods of treating skin changes by topical application of these carboxylic acid-substituted idebenone derivatives, and their methods of synthesis. The carboxylic acid-substituted idebenone derivatives of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance. When included in a topical composition, the carboxylic acid-substituted idebenone derivatives of the present invention have an antioxidant effect that is useful in treating a skin change.
Type:
Application
Filed:
October 6, 2009
Publication date:
April 8, 2010
Applicant:
PCR Technology Holdings, LC
Inventors:
Falko Diedrich, Joseph A. Lewis, II, Joseph C. DiNardo, Birgit Neudecker, Eberhard Wieland
Abstract: A pure chlorine dioxide solution includes a chlorine dioxide gas dissolved therein, a chlorite, and a pH adjuster which is an acid or a salt thereof having a buffering property whose pH is 2.5 to 6.8 as a 5% aqueous solution at 25° C.
Abstract: A mixed micellar pharmaceutical formulation includes a micellar pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanylglycine, glycerine, polyglycerin, lysine, polylysine, triolein and mixtures thereof. Each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt. % of the total formulation, and the total concentration of absorption enhancing compounds are is less than 50 wt./wt. % of the formulation.
Abstract: A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product.
Abstract: Ruthenium containing compounds and compositions which inhibit the cellular mitochondrial electron transfer mechanism by providing electrochemically-generated oxygen to an oxygen-deprived environment. Also provided are pharmaceutical compositions containing the same and methods for treating cancer using the pharmaceutical compositions.
Abstract: Compositions and methods for preventing or reducing vasoconstriction in a mammal following administration of an artificial oxygen carrier (e.g., a hemoglobin-based oxygen carrier) are disclosed. The methods include administering to a mammal a composition containing an artificial oxygen carrier in combination with one or more of a nitric oxide-releasing compound, a therapeutic gas containing gaseous nitric oxide, a phosphodiesterase inhibitor, and/or a soluble guanylate cyclase sensitizer.
Type:
Application
Filed:
November 6, 2007
Publication date:
March 4, 2010
Applicant:
The General Hospital Corporation
Inventors:
Warren M. Zapol, Binglan Yu, Fumito Ichinose
Abstract: A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, comprising an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermohygrometric conditions and with standard tabletting equipment. A pre-granulation process is also disclosed.
Type:
Application
Filed:
October 26, 2009
Publication date:
February 25, 2010
Applicant:
Chiesi Farmaceutici S.p.A.
Inventors:
Paolo Chiesi, Paolo Ventura, Rosa Mezzadri, Gaetano Brambilla, Daniela Acerbi
Abstract: A pesticidal aerosol composition, containing 3-phenoxybenzyl ester compound represented by Formula (I): wherein, X represents a hydrogen atom or a cyano group; Z represents a hydrogen atom or a fluorine atom; and R1 and R2 each independently represent a hydrogen atom, a C1-C3 alkyl group that may be substituted with halogen atoms, or a halogen atom; 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate, an organic solvent, and a propellant has an excellent pesticidal activity.
Abstract: This invention provides an effervescent solid form that dissolves in cold water quickly enough to not disappoint consumers yet not so quickly that the visual interest generated during the effervescent reaction is lost. This performance is achieved by forming effervescent particles that are dense enough to retard dissolution and small enough to not take too long to dissolve. The aim of this invention is to provide a beverage in solid effervescent form that takes between about 30 and about 120 seconds to dissolve in warm water. The granules may carry functional additives such as flavors, vitamins, minerals, sweeteners, colors and drugs. The granules may also be compounded of materials intended to provide relief from skin or topical discomfort, as in the form of a wash or bath additive. The granules may also be formulated to provide cleaning agents, such as ceramic cleaners and denture cleaners.
Type:
Application
Filed:
August 6, 2009
Publication date:
February 11, 2010
Applicant:
PHYZZ, INC.
Inventors:
ALLEN RAU, Nicole Quinn, Donald Stadolnik, Eric Sterner
Abstract: The present invention relates to method for killing various mold spores appearing on a surface by applying a composition comprising water soluble blast media and antimicrobial agent to the surface. The composition can be applied by a pressurized blasting apparatus or can be applied directly by any coating method. The composition can be immediately rinsed off the surface or applied directly to a surface and allowed to set and stay in contact with mold and mold spores.
Type:
Application
Filed:
December 13, 2007
Publication date:
February 4, 2010
Inventors:
Steven A. Bolkan, Andrew Logan, JR., Melvin H. Czechowski
Abstract: A stable composition for rapid delivery by inhalation to the lungs, and subsequently to the bloodstream, is provided. The composition comprises a therapeutically effective amount of delta-9-tetrahydrocannabinol in a pharmaceutically-acceptable semiaqueous solvent comprising an alcohol, water and a glycol. A composition comprising volumetric ratios of ethanol:water:propylene glycol selected from those in the range of from 10-70:10-30:20-80, respectively, having a combined total of 100 is also provided. A sterile and/or preserved sealed unit-or multi-unit dosage form of delta-9-tetrahydrocannabinol is further provided.
Type:
Grant
Filed:
September 5, 2003
Date of Patent:
January 19, 2010
Assignee:
Unimed Pharmaceuticals, LLC
Inventors:
Andrea M McPhillips, Julia J Economou, Mahendra G Dedhiya, Beverly Ann Wynne
Abstract: A composition comprising iron pyrophosphate and copper citrate does not exhibit the unpleasant taste and aftertaste usually found with iron supplements.
Abstract: A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
Type:
Grant
Filed:
May 9, 2006
Date of Patent:
January 12, 2010
Assignee:
Foamix Ltd.
Inventors:
Dov Tamarkin, Doron Friedman, Alex Besonov
Abstract: A self gassing composition comprising at least one surfactant and a fermentation base including a gas producing organism and at least one sugar is disclosed. Use of a nonionic surfactant in the self gassing composition allows the fermentation base to continue reacting and producing gas. Additionally, a personal care cleansing product and method for storing and delivering an aqueous composition having at least one surfactant and pressurized gas dissolved therein is disclosed. In one aspect, the composition is stored in an internal reservoir in a container such that when a sealing device is removed from a valveless opening, the composition foams and plumes out the opening of the container as the gas dissolved in the composition is released. In addition to the self gassing composition, a pressurized gas may be injected into a surfactant composition to produce the gas pressurized cleaning composition.
Type:
Application
Filed:
June 30, 2008
Publication date:
December 31, 2009
Inventors:
Jeffery Richard Seidling, Scott W. Wenzel, Stacy Averic Mundschau, David W. Koenig
Abstract: The present invention relates to novel drug combinations which, besides one or more, preferably on compound of the general formula (1), wherein remainder n, A, R1, R2, and R3 can have the meanings given in the claims and in the description comprise at least one further active ingredient 2 and method for the production thereof and the use thereof as drugs.
Type:
Application
Filed:
August 3, 2007
Publication date:
December 31, 2009
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Inventors:
Ingo Konetzki, Thierry Bouyssou, Sabine Pestel, Andreas Schnapp
Abstract: A method is described for delivering liquid active agents for deodorising and disinfecting an enclosed space (1), in particular an animal enclosure, wherein the active agents are sprayed with the aid of a compressed gas by means of atomizing nozzles (2) distributed in the enclosed space (1). In order to provide advantageous delivery conditions it is proposed that the active agents in the atomising nozzles (2) are selectively atomised either by means of fine atomisation using a high gas pressure to create an aerosol or by means of coarse atomisation using a low gas pressure to create a sinking fluid mist.
Abstract: The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.
Type:
Application
Filed:
July 8, 2009
Publication date:
December 24, 2009
Applicant:
Foamix Ltd.
Inventors:
Dov TAMARKIN, Doron FRIEDMAN, Meir EINI
Abstract: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a glucocorticosteroid for the treatment of asthma, chronic obstructive pulmonary disease, allergic rhinitis, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.
Abstract: A method and apparatus for generating nano particles, including but not limited to nano particles of Ceo, at high concentration. The invention uses a solid aerosol disperser in communication with a furnace tube having a vaporization chamber and a dilution chamber. A heating element surrounds the furnace tube. Heat from the heating element heats bulk materials contained within a gas flow in the vaporization chamber to a temperature sufficient to convert the bulk materials to a vapor phase. Vaporized bulk materials are then moved to a dilution chamber, where an inert gas is introduced through a dilution gas port. The flow of the inert gas into the dilution chamber through the dilution gas port is sufficient to eject the bulk material from the exit of the dilution chamber, thereby condensing the bulk material into nano sized particles in a gas flow of sufficient volume to prevent agglomeration of the nano sized particles.
Type:
Application
Filed:
March 2, 2007
Publication date:
December 24, 2009
Inventors:
Amit Gupta, William C. Forsythe, Mark L. Clark
Abstract: A composition for solvating one or more active agents in an aqueous solution which is suitable for dispensing as a compressed gas aerosol composition is disclosed. The composition includes at least one surfactant, at least one active agent (such as a fragrance or an insecticide), and a compressed gas propellant. The at least one surfactant is preferably present in an amount from about 0.1 wt. % to about 3 wt. %. The at least one active agent is preferably present in an amount from about 0.1 wt. % to about 2 wt. %. The compressed gas propellant is preferably present in an amount from about 0.1 wt. % to about 1 wt. %. The total surfactant weight to active agent weight ratio for the composition is preferably about 1:3 to 5:1. The composition uses a reduced amount of surfactant and active agent thereby allowing for a more efficient active agent loading and a reduced stickiness or tackiness on surfaces contacted during use.
Type:
Application
Filed:
June 13, 2008
Publication date:
December 17, 2009
Inventors:
Paul A. Clark, Richard S. Valpey, III, Maciej K. Tasz
Abstract: A pharmaceutical topical spray composition including a topical corticosteroid, an alcohol, a propellant, isopropyl myristate, and a blend of botanic seed oils is described. The blend of botanic seed oils may include three or more botanic seed oils prepared using a cold press method. A method for treating an inflammatory skin condition by administering the pharmaceutical topical spray composition to the skin of a mammal is also described. The pharmaceutical composition is effective in the treatment of inflammatory skin conditions without the need for zinc pyrithione, undecylenic acid, or a detergent.
Abstract: A nutritional supplement useful for promoting good overall health and relieving minor aches and pains associated with inflammation and muscle soreness includes a plurality of active herbal ingredients (turmeric extract, white willow extract, passion flower extract, valerian root extract, and/or licorice root extract), a plurality of non-herbal active ingredients (magnesium glycinate, vitamin B1 (thiamine HCl), vitamin B2 (riboflavin), vitamin B3 (niacinamide), vitamin B6 (pyridoxine HCl), folic acid, vitamin B12, and/or beta carotene). The nutritional supplement may be in the form of an effervescent tablet that is dissolvable in a potable liquid and can include one or more sweeteners and flavorings.
Abstract: A hair treatment composition, comprising a silicone pressure sensitive adhesive wherein the composition comprises less than 0.5 wt % of water.
Abstract: A delivery system and method for delivering an aerosol drug to an infant. The delivery device comprises a) a diagnostic module configured to provide geometrical properties of the nasal airway of the infant as output; b) a dosing system configured to produce an aerosol drug dose, based upon the output of the diagnostic module, that is predicted to ensure that a desired amount of the aerosol drug dose reaches the lungs of the infant in use; and c) an infant facemask connected to receive the aerosol drug dose from the dosing system for supply of the aerosol drug dose to the infant.
Type:
Application
Filed:
May 13, 2009
Publication date:
November 19, 2009
Inventors:
Warren H. Finlay, John Storey-Bishoff, Michelle Noga
Abstract: The present invention provides compositions for the therapeutic and/or cosmetic treatment of Elastin comprising tissues. Therapeutic and cosmetic compositions comprising an elastin digest stimulate the endogenous production of Elastin and appear to enhance the elasticity of the skin and provide an external supply of peptide precursors of Elastin that penetrate into the tissue to which it is applied. The present invention describes compositions containing an elastin digest derived from proteolytic digestion of insoluble elastin derived from mammalian ligaments with a protein digesting composition, such as proteinase K. The elastin digest is a mixture of elastin peptides wherein the elastin peptide mixture comprises peptides of the sequence GXXPG, wherein X represents one of the natural amino acids. The elastin digest of the present invention may also comprise epitopes of cytokines, growth factors and di-peptides.
Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Abstract: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention.
Abstract: A composition for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler, filling of an aerosol container and use of the composition for the administration of active materials by inhalation.
Type:
Grant
Filed:
May 12, 2003
Date of Patent:
October 13, 2009
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
David Lewis, Davis Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
Abstract: The foam product for hair treatment includes a composition containing a cationic cellulose derivative, chitosan, acid for partial or complete neutralization of the chitosan and a suitable solvent. The weight ratio of the cationic cellulose derivative to the chitosan is less than 2. The composition is either provided with a propellant or is foamed with a mechanically operated foam-making device.
Type:
Grant
Filed:
May 12, 2003
Date of Patent:
October 6, 2009
Assignee:
Wella AG
Inventors:
Susanne Birkel, Harald Wendel, Michael Franzke, Manuela Hannich
Abstract: The present invention relates to the use of halides and halide salts for the treatment of microbial infections, including those caused by bacteria, fungi and viruses. The present invention takes advantage of endogenous immune function and augments this system using a non-toxic and inexpensive reagent that can be delivered to mucosal surfaces, for example, orally, topically, opthalmically and via inhalation.
Type:
Application
Filed:
January 9, 2009
Publication date:
October 1, 2009
Inventors:
BOTOND BANFI, Anthony Fischer, Joseph Zabner, Lakshmi Durairaj, Daniel Lorentzen, Paul B. McCray, JR.
Abstract: Use of particulate bulking agents having an extremely small mass median diameter of less than one micron, preferably less than 300 nm, in pharmaceutical aerosol formulations comprising a suspension of drug particles in a propellant. Examples of bulking agents include ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts, urea, and propyliodone.
Type:
Application
Filed:
May 26, 2009
Publication date:
October 1, 2009
Inventors:
Philip A. Jinks, Lesley McKenzie, James T. Lister
Abstract: The present disclosure is drawn to disinfectant hand sanitizing compositions. In one embodiment, a hand sanitizing compositions can include from 10 to 1500 ppm colloidal silver, from 0.01 wt % to 30 wt % alcohol, at least 70 wt % water, and a thickening agent. The hand sanitizers can provide continued sanitization for an extended period of time and can be formulated to be dispensed as self-supporting foams.
Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
Type:
Application
Filed:
May 8, 2009
Publication date:
September 10, 2009
Applicant:
THERAVANCE, INC.
Inventors:
Mathai Mammen, Yu-Hua Ji, YongQi Mu, Craig Husfeld, Li Li
Abstract: Esters of L-carnitine and alkanoyl L-carnitines are described which can be used as cationic lipids for the intracellular delivery of pharmacologically active compounds. New esters of L-carnitine and alkanoyl L-carnitines of formula (I) are also disclosed wherein the R groups are as defined in the description.
Abstract: Described herein are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.
Type:
Application
Filed:
October 6, 2008
Publication date:
August 27, 2009
Applicants:
Cephalon, Inc., CIMA LABS INC.
Inventors:
Vikas Agarwal, Brian I. Hague, Rajendra K. Khankari
Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.
Type:
Application
Filed:
February 13, 2009
Publication date:
August 20, 2009
Applicant:
Board of Regents, The University of Texas System
Inventors:
Keith P. Johnston, Joshua Engstrom, Jasmine Tam
Abstract: The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
August 18, 2009
Assignee:
Foamix Ltd.
Inventors:
Dov Tamarkin, Doron Friedman, Meir Eini
Abstract: The object of the present invention is to provide an all-natural dietary supplement formulation that may be beneficial to the management of behavioral and neurological symptoms associated with autism spectrum disorders; symptoms that may not be effectively improved by conventional drug treatment and behavioral therapy alone.
Abstract: A device for spraying a cosmetic or dermatological composition may comprise an ultrasound or electrostatic spray head, an airflow generator for entraining a spray of composition particles atomized by the spray head and a conditioning device, the conditioning device arranged to modify the temperature of the outgoing stream of air.
Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed.
Type:
Application
Filed:
April 24, 2009
Publication date:
August 13, 2009
Applicant:
CIMA LABS INC.
Inventors:
Sathasivan Indiran Pather, Rajendra K. Khankari, Jonathan D. Eichman, Joseph R. Robinson, John Hontz
Abstract: An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants by Xylella fastidiosa using materials derived from bactericidal metals wherein one metal is silver. The candidate bactericidal metal is preferably introduced in metallic, nanocrystalline, salt form, chelated form, or otherwise coupled form. Metal atoms, ions, molecules, or clusters are introduced to the plant to the plant by injection, ballistic insertion, pneumatic insertion, mechanical insertion, manual insertion, root application, aerosolization, or spray in sufficient concentration to treat, cure, and/or prevent plant disease or reduced productivity caused by X. fastidiosa.
Abstract: Disclosed here is a stable, aqueous aerosol oil-in-water emulsion foam composition useful in dispensing a wide variety of therapeutic agents as an alternative to solid or liquid dosage forms which may be difficult to swallow or where the quantity of liquid intake is to be limited. More particularly, this invention discloses foam compositions containing a calcium compound in high concentration to be used as food supplement with an unexpectedly pleasant taste and little after-taste allowing better patient compliance.
Abstract: The invention relates to an aerosol, in which a phase containing a solid substance is dispersed into a gaseous dispersant. The aim of the invention is to achieve a particularly effective anti-inflammatory action for the treatment of respiratory diseases. According to the invention, a depot is contained in the dispersed phase, said depot releasing silver ions when it comes into contact with water.
Type:
Application
Filed:
February 22, 2007
Publication date:
July 30, 2009
Applicant:
BIO-GATE AG
Inventors:
Knud Klingler, Peter Steinrucke, Thorsten Bechert
Abstract: Compositions including an isolated Bacillus species, spores or an extracellular product of B. coagulans, suitable for topical application, for inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus are disclosed. Methods of inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus by topical application of compositions that include an isolated Bacillus species, spores or an extracellular product of a B. coagulans strain are disclosed.
Abstract: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).
Abstract: There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the color agent is one or more agents selected from the group consisting of a colored active agent, a colored indicator, a colored excipient, a pigment, a dye, a colorant and a coloring agent; b) a propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the base composition has a first color; and wherein the foam comprising the colored or colorable topical composition has a second color upon dispensing from an aerosol container, and wherein the first color and the second color are visually different. There is also described a method of changing color, a method of administration, a use as a diagnostic and a kit.
Type:
Application
Filed:
January 8, 2009
Publication date:
July 9, 2009
Inventors:
Dov TAMARKIN, Doron FRIEDMAN, Meir EINI
Abstract: A pharmaceutical composition comprising an anticholinergic and a betamimetic of formula 2 optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of asthma, COPD, or other inflammatory or obstructive respiratory complaints.
Type:
Application
Filed:
January 7, 2009
Publication date:
June 18, 2009
Inventors:
Christopher John Montague Meade, Michel Pairet, Michael P. Pieper, Ingo Konetzki
Abstract: The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.